[HTML][HTML] Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis
U Schmid, KH Liesenfeld, A Fleury, C Dallinger… - Cancer chemotherapy …, 2018 - Springer
Purpose A population pharmacokinetic model was developed for nintedanib in patients with
non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of …
non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of …
[HTML][HTML] Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis
U Schmid, KH Liesenfeld, A Fleury… - Cancer …, 2018 - ncbi.nlm.nih.gov
Purpose A population pharmacokinetic model was developed for nintedanib in patients with
non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of …
non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of …
Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis
U Schmid, KH Liesenfeld, A Fleury… - Cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose A population pharmacokinetic model was developed for nintedanib in patients with
non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of …
non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of …
Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
U Schmid, KH Liesenfeld, A Fleury… - Cancer …, 2017 - europepmc.org
Purpose A population pharmacokinetic model was developed for nintedanib in patients with
non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of …
non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of …
Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis
U Schmid, KH Liesenfeld, A Fleury… - Cancer …, 2018 - search.proquest.com
Purpose A population pharmacokinetic model was developed for nintedanib in patients with
non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of …
non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of …
Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
U Schmid, KH Liesenfeld, A Fleury… - Cancer …, 2017 - europepmc.org
Purpose A population pharmacokinetic model was developed for nintedanib in patients with
non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of …
non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of …